BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax share withholding

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. director and CEO Neil Kumar reported equity compensation-related transactions involving restricted stock units (RSUs) and common stock on February 16, 2026. He acquired multiple blocks of common stock at $0.00 per share through the exercise or conversion of RSUs, which each represent a contingent right to receive one share of common stock.

To cover tax obligations triggered by the vesting of 64,698 RSU-based shares, 30,970 shares of common stock were disposed of at $75.25 per share via share withholding, rather than an open-market sale. Following these transactions, he continued to hold a significant number of shares directly, and additional common stock is held indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he is a co-trustee. He disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/16/2026		M		33,544	A	(1)	262,320	D
Common Stock	02/16/2026		M		19,600	A	(1)	281,920	D
Common Stock	02/16/2026		M		11,554	A	(1)	293,474	D
Common Stock	02/16/2026		F		30,970(2)	D	$75.25	262,504	D
Common Stock								675,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								4,478,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/16/2026		M			33,544	(4)	(4)	Common Stock	33,544	$0	134,176	D
Restricted Stock Units	(1)	02/16/2026		M			19,600	(5)	(5)	Common Stock	19,600	$0	156,794	D
Restricted Stock Units	(1)	02/16/2026		M			11,554	(6)	(6)	Common Stock	11,554	$0	138,645	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,698 shares of Common Stock underlying the Reporting Person's RSUs.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

5. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BridgeBio Pharma (BBIO) CEO Neil Kumar report?

Neil Kumar reported RSU-based equity transactions, acquiring common stock at $0.00 per share via RSU exercises and disposing of 30,970 shares at $75.25 per share to satisfy tax withholding obligations associated with the vesting of 64,698 RSU-linked shares of BridgeBio Pharma common stock.

How were BridgeBio Pharma (BBIO) RSUs treated in Neil Kumar’s Form 4?

Each restricted stock unit represents a contingent right to receive one share of BridgeBio Pharma common stock. The RSUs converted into common stock at $0.00 per share on February 16, 2026, reflecting equity compensation vesting rather than an open-market purchase of shares by Neil Kumar.

Why did Neil Kumar dispose of BridgeBio Pharma (BBIO) shares at $75.25?

Neil Kumar disposed of 30,970 BridgeBio Pharma common shares at $75.25 each to satisfy tax obligations arising from the vesting of 64,698 RSU-based shares. This disposition was structured as share withholding for taxes, not as a discretionary open-market sale transaction by the CEO.

What is the vesting schedule for Neil Kumar’s BridgeBio Pharma (BBIO) RSUs?

One RSU grant vested 1/16 of its shares on May 16, 2023, another on May 16, 2024, and a third on May 16, 2025. Each then vests 1/16 quarterly, subject to his continued service, and the RSUs have no expiration date according to the disclosed footnotes.

How are BridgeBio Pharma (BBIO) shares held through the Kumar family trusts treated?

Some BridgeBio Pharma common stock is held indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where Neil Kumar is a co-trustee. He disclaims beneficial ownership of these trust-held shares except to the extent of any pecuniary interest he may have.

Did Neil Kumar’s Form 4 indicate open-market buying or selling of BBIO shares?

The Form 4 showed RSU exercises at $0.00 per share and a tax-withholding disposition at $75.25 per share. It did not describe open-market purchases or discretionary sales; the key activity relates to equity compensation vesting and associated tax settlement in BridgeBio Pharma shares.